Re: Importing citations from ovid

<1>
Unique Identifier
  10071455
Record Owner
  NLM
Authors
  Yoshida M.  Karasawa M.  Naruse T.  Fukuda M.  Hirashima K.  Oh H.  Ninomiya H.  Abe T.  Saito K.  Shishido H.  Moriyama Y.  Shibata A.  Motoyoshi K.  Nagata N.  Miura Y.
Institution
  Fourth Department of Internal Medicine, Teikyo University School of Medicine, Kawasaki City, Japan.
Title
  Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.
Source
  International Journal of Hematology.  69(2):81-8, 1999 Feb.
Abbreviated Source
  Int J Hematol.  69(2):81-8, 1999 Feb.
Publication Notes
  The publication year is for the print issue of this journal.  
NLM Journal Code
  a7f, 9111627
Journal Subset
  IM
Country of Publication
  Ireland
MeSH Subject Headings
    Adolescent
    Aged
    Aged, 80 and over
    Anti-Bacterial Agents/ad [Administration & Dosage]
    *Anti-Bacterial Agents/tu [Therapeutic Use]
    Antibiotics, Combined/ad [Administration & Dosage]
    *Antibiotics, Combined/tu [Therapeutic Use]
    Bacteremia/dt [Drug Therapy]
    Bacteremia/et [Etiology]
    *Bacterial Infections/dt [Drug Therapy]
    Bacterial Infections/et [Etiology]
    Cephalosporins/ad [Administration & Dosage]
    *Cephalosporins/tu [Therapeutic Use]
    Comparative Study
    Drug Therapy, Combination
    Female
    *Fever/et [Etiology]
    Filgrastim/ad [Administration & Dosage]
    Filgrastim/ae [Adverse Effects]
    *Filgrastim/tu [Therapeutic Use]
    Granulocyte Colony-Stimulating Factor/ad [Administration & Dosage]
    Granulocyte Colony-Stimulating Factor/ae [Adverse Effects]
    *Granulocyte Colony-Stimulating Factor/tu [Therapeutic Use]
    *Hematologic Neoplasms/co [Complications]
    Hematologic Neoplasms/dt [Drug Therapy]
    Human
    Immunocompromised Host
    Leukocyte Count/de [Drug Effects]
    Male
    Middle Aged
    Neutropenia/ci [Chemically Induced]
    Neutropenia/co [Complications]
    *Neutropenia/dt [Drug Therapy]
    Pneumonia/dt [Drug Therapy]
    Pneumonia/et [Etiology]
    Recombinant Proteins/ad [Administration & Dosage]
    Recombinant Proteins/ae [Adverse Effects]
    Recombinant Proteins/tu [Therapeutic Use]
    Tobramycin/ad [Administration & Dosage]
    *Tobramycin/tu [Therapeutic Use]
    Treatment Outcome
Abstract
  The clinical effects of concomitant use of granulocyte-colony stimulating factor (G-CSF) on empiric antibiotic therapy in febrile neutropenic patients were evaluated in a randomized fashion. Two hundred and fourteen neutropenic febrile episodes (neutrophil counts < 1.0 x 10(9)/l) were treated with flomoxef sodium and tobramycin with or without G-CSF. The resolution of fever at day 4 (excellent response) or at day 7 (good response) was deemed effective. Among 157 evaluable episodes, the observed excellent responses were 31 (38.8%) and the good responses were 20 (25.0%) in the G-CSF group; those in the control group were 26 (33.8%) and 25 (32.5%), respectively. The overall efficacy rate was 63.8% (51/80) in the G-CSF group and 66.2% (51/77) in the control group (not significant). The initial neutrophil count was 0.186 +/- 0.249 x 10(9)/l in the G-CSF group and 0.235 +/- 0.290 x 10(9)/l in the control group, and rose to 2.889 +/- 4.198 x 10(9)/l and 0.522 +/- 0.844 x 10(9)/l, respectively, at day 7. These results indicate that G-CSF does not affect the rate of response to empiric antibiotic therapy in febrile neutropenic patients, although a significant effect of G-CSF was observed on neutrophil recovery.
CAS Registry/EC Number
  0 (Anti-Bacterial Agents).  0 (Antibiotics, Combined).  0 (Cephalosporins).  0 (Recombinant Proteins).  121181-53-1 (Filgrastim).  135968-09-1 (lenograstim).  143011-72-7 (Granulocyte Colony-Stimulating Factor).  32986-56-4 (Tobramycin).  92823-03-5 (flomoxef).
ISSN
  0925-5710
Publication Type
  Clinical Trial.  Journal Article.  Multicenter Study.  Randomized Controlled Trial.
Language
  English
Entry Date
  19990422
Revision Date
  20040401
Update Date
  20040402


<2>
Unique Identifier
  9637161
Record Owner
  NLM
Authors
  Ishikawa K.  Tanaka H.  Matsuoka T.  Shimazu T.  Yoshioka T.  Sugimoto H.
Institution
  Department of Traumatology, Osaka University Medical School, Japan. ishikawa-jOoXdkz4CfcJTGarn5fKFPHXLTXbXKZ9zw2xav70ESE@public.gmane.org
Title
  Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia.
Source
  Journal of Trauma-Injury Infection & Critical Care.  44(6):1047-54; discussion 1054-5, 1998 Jun.
Abbreviated Source
  J Trauma.  44(6):1047-54; discussion 1054-5, 1998 Jun.
Publication Notes
  The publication year is for the print issue of this journal.  
NLM Journal Code
  kaf, 0376373
Journal Subset
  AIM, IM
Country of Publication
  United States
MeSH Subject Headings
    APACHE
    *Adjuvants, Immunologic/tu [Therapeutic Use]
    Adolescent
    Adult
    Aged
    Biological Markers/bl [Blood]
    C-Reactive Protein/me [Metabolism]
    Female
    *Granulocyte Colony-Stimulating Factor/tu [Therapeutic Use]
    Human
    Interleukin-1/bl [Blood]
    Interleukin-6/bl [Blood]
    Interleukin-8/bl [Blood]
    Leukocyte Count
    Leukocyte Elastase/bl [Blood]
    Male
    Middle Aged
    Multiple Organ Failure/bl [Blood]
    Multiple Organ Failure/et [Etiology]
    Neutropenia/bl [Blood]
    Neutropenia/co [Complications]
    *Neutropenia/dt [Drug Therapy]
    Recombinant Proteins/tu [Therapeutic Use]
    Sepsis/bl [Blood]
    Sepsis/co [Complications]
    *Sepsis/dt [Drug Therapy]
    Tumor Necrosis Factor/me [Metabolism]
Abstract
  OBJECTIVE: The objective of this study was to determine the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration in septic patients with neutropenia. METHODS: Twenty consecutive septic patients were administered rhG-CSF subcutaneously (2 microg x kg(-1) x d(-1)) for 5 days (group G). They were compared with 14 septic patients treated earlier without rhG-CSF (group N). All patients in both groups met the criteria of total leukocyte count (TLC) less than 5,000/mm3 and C-reactive protein (CRP) more than 10 mg/dL. Changes in TLC, absolute neutrophil count (ANC), CRP, respiratory index (RI), Acute Physiology and Chronic Health Evaluation (APACHE) II score, and Goris's Multiple Organ Failure (MOF) index were evaluated. In addition, nucleated cell count (NCC), differentiation in bone marrow aspiration, neutrophil phagocytic and bactericidal activity, serum concentrations of interleukin-6 (IL-6) and IL-8 as inflammatory markers, and plasma concentration of leukocyte elastase (LE) as an indicator of the tissue injury were evaluated in group G. RESULTS: In group G, TLC, ANC, NCC, and neutrophil functions increased significantly, whereas CRP, IL-6, and IL-8 decreased reciprocally. There was no deterioration of LE and RI. Consequently, the APACHE II score and MOF index improved. In group N, however, CRP showed no change concomitant with the APACHE II score and MOF index. CONCLUSION: Administration of rhG-CSF attenuates inflammatory responses without inducing tissue injury in septic patients with neutropenia.
CAS Registry/EC Number
  0 (Adjuvants, Immunologic).  0 (Biological Markers).  0 (Interleukin-1).  0 (Interleukin-6).  0 (Interleukin-8).  0 (Recombinant Proteins).  0 (Tumor Necrosis Factor).  135968-09-1 (lenograstim).  143011-72-7 (Granulocyte Colony-Stimulating Factor).  9007-41-4 (C-Reactive Protein).  EC 3-4-21-37 (Leukocyte Elastase).
ISSN
  0022-5282
Publication Type
  Journal Article.
Language
  English
Entry Date
  19980702
Revision Date
  20040401
Update Date
  20040402


<3>
Unique Identifier
  8983890
Record Owner
  NLM
Authors
  Niitsu N.  Umeda M.
Institution
  First Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan.
Title
  Fungemia in patients with hematologic malignancies: therapeutic effects of concomitant administration of fluconazole and granulocyte-colony-stimulating factor.
Source
  Chemotherapy.  42(3):215-19, 1996 May-Jun.
Abbreviated Source
  Chemotherapy.  42(3):215-19, 1996 May-Jun.
Publication Notes
  The publication year is for the print issue of this journal.  
NLM Journal Code
  d15, 0144731
Journal Subset
  IM
Country of Publication
  Switzerland
MeSH Subject Headings
    *Adjuvants, Immunologic/tu [Therapeutic Use]
    *Antifungal Agents/tu [Therapeutic Use]
    Drug Therapy, Combination
    *Fluconazole/tu [Therapeutic Use]
    Fungemia/bl [Blood]
    Fungemia/di [Diagnosis]
    *Fungemia/dt [Drug Therapy]
    *Glucans/bl [Blood]
    *Granulocyte Colony-Stimulating Factor/tu [Therapeutic Use]
    Hematologic Diseases/co [Complications]
    Human
    Recombinant Proteins/tu [Therapeutic Use]
Abstract
  Serum (beta 1-->3)-D-glucan was elevated in 34 of 126 patients (27%) with hematologic malignancy who were clinically suspected of having a deep-seated mycosis. Although 11 patients (8.8%) were thought to have fungemia, fungi were isolated from blood culture in only 4. These results suggest that measurement of serum beta-D-glucan is useful for early diagnosis. Therapy with fluconazole (FLCZ) was effective in 9 of 11 patients (81.8%) suspected of having fungemia. Fungemia responded in 5 of 7 patients who were given granulocyte-colony-stimulating factor (G-CSF) concomitantly with FLCZ. This result suggested that administration of G-CSF with FLCZ was useful therapy for fungemia, which may occur during granulocytopenia following chemotherapy with anticancer agents.
CAS Registry/EC Number
  0 (Adjuvants, Immunologic).  0 (Antifungal Agents).  0 (Glucans).  0 (Recombinant Proteins).  135968-09-1 (lenograstim).  143011-72-7 (Granulocyte Colony-Stimulating Factor).  86386-73-4 (Fluconazole).
ISSN
  0009-3157
Publication Type
  Journal Article.
Language
  English
Entry Date
  19970107
Revision Date
  20040401
Update Date
  20040402


<4>
Unique Identifier
  2938842
Record Owner
  NLM
Authors
  Lee HC.  Lum BK.
Title
  Protective action of calcium entry blockers in endotoxin shock.[erratum appears in Circ Shock 1986;20(1):81].
Source
  Circulatory Shock.  18(3):193-203, 1986.
Abbreviated Source
  Circ Shock.  18(3):193-203, 1986.
Publication Notes
  The publication year is for the print issue of this journal.  
NLM Journal Code
  c9y, 0414112
Journal Subset
  IM
Country of Publication
  United States
MeSH Subject Headings
    Animals
    Blood Pressure
    *Calcium Channel Blockers/tu [Therapeutic Use]
    Comparative Study
    Escherichia coli
    Heart Rate
    Male
    Nifedipine/aa [Analogs & Derivatives]
    Nifedipine/tu [Therapeutic Use]
    Nitrendipine
    Rats
    Rats, Inbred Strains
    *Shock, Septic/dt [Drug Therapy]
    Shock, Septic/mo [Mortality]
    Support, Non-U.S. Gov't
    Verapamil/tu [Therapeutic Use]
Abstract
  Calcium entry blockers (CEBs) have been reported to protect against cellular necrosis caused by experimental ischemia and the beneficial effect has been related to prevention of ischemia-induced calcium overload by the CEBs. Since circulatory shock can be expected to produce generalized tissue hypoxia, the possibility that CEBs might be beneficial in shock produced by endotoxin was investigated. In control male Wistar rats, a 10-mg/kg dose of E. coli endotoxin (Difco 0127:B8) produced a fall in blood pressure and a transient increase followed by a progressive slowing of the heart rate. Mortality 48 hours after endotoxin (10 mg/kg) was 84%. The calcium entry blockers (CEBs) verapamil, nitrendipine, and nilvadipine [corrected], administered i.v. 15 min before endotoxin, produced a dose-dependent reduction in mortality. The CEBs were less effective when given as post-treatment (15 to 30 min after endotoxin). Measurements of total tissue and mitochondrial calcium levels in control rats revealed that endotoxin did not produce an increase in the calcium content of heart, lung, pancreas, small intestine, kidney, and aorta. Since increased cellular calcium levels did not occur in response to endotoxin, the protection induced by CEBs in endotoxin shock does not appear to be related to prevention of calcium overload; however, the possibility that the CEBs may beneficially prevent an excessive accumulation of calcium in discrete cells or intracellular compartments (which may not be detected by our methods) cannot be excluded.
CAS Registry/EC Number
  0 (Calcium Channel Blockers).  21829-25-4 (Nifedipine).  39562-70-4 (Nitrendipine).  52-53-9 (Verapamil).  75530-68-6 (nilvadipine).
ISSN
  0092-6213
Publication Type
  Journal Article.
Language
  English
Entry Date
  19860606
Revision Date
  20040331
Update Date
  20040401


<5>
Unique Identifier
  12230418
Record Owner
  NLM
Authors
  Husain S.  Slobodkin D.  Weinstein RA.
Institution
  University of Pittsburgh Medical Center, PA, USA.
Title
  Pneumococcal vaccination: analysis of opportunities in an inner-city hospital.[erratum appears in Arch Intern Med. 2004 Mar 8;164(5):573].
Source
  Archives of Internal Medicine.  162(17):1961-5, 2002 Sep 23.
Abbreviated Source
  Arch Intern Med.  162(17):1961-5, 2002 Sep 23.
Publication Notes
  The publication year is for the print issue of this journal.  
NLM Journal Code
  0372440, 7fs
Journal Subset
  AIM, IM
Country of Publication
  United States
MeSH Subject Headings
    Adolescent
    Adult
    Aged
    Bacteremia/ec [Economics]
    Bacteremia/mo [Mortality]
    Bacteremia/pc [Prevention & Control]
    Chicago/ep [Epidemiology]
    Cohort Studies
    Comparative Study
    Cost-Benefit Analysis
    Emergency Service, Hospital/ec [Economics]
    Female
    Hospitals, Municipal/ec [Economics]
    Human
    Male
    Middle Aged
    Outpatient Clinics, Hospital/ec [Economics]
    Patient Admission/ec [Economics]
    Pneumococcal Infections/ec [Economics]
    Pneumococcal Infections/mo [Mortality]
    Pneumococcal Infections/pc [Prevention & Control]
    Pneumococcal Vaccines/ec [Economics]
    *Pneumococcal Vaccines
    Prevalence
    Retrospective Studies
    Risk Factors
    Survival Analysis
    Treatment Outcome
Abstract
  BACKGROUND: Adult pneumococcal vaccination rates for persons at risk of developing pneumococcal disease remain below desired levels. Various sites within the hospital (inpatient medicine wards [IMWs], general medicine clinics [GMCs], and emergency departments [EDs]) have been suggested as venues for administering vaccination. The cost-effectiveness of such sites for delivery of pneumococcal vaccination is not known. OBJECTIVE: To compare the potential coverage of at-risk patients and cost of pneumococcal vaccination delivered in an ED, GMC, and IMWs. METHODS: We studied a retrospective cohort of 300 patients with pneumococcal bacteremia who had been hospitalized at Cook County Hospital, an inner-city Chicago public teaching hospital, from January 1994 through December 1998. We measured the presence of risk factors, as defined by the Centers for Disease Control and Prevention, for developing pneumococcal disease prior to index admission for bacteremia; patient use of ED, GMC, and IMWs from 4 weeks to 5 years before index admission; size of target population for vaccination in each site; and cost benefit of a pneumococcal vaccination strategy at each site. RESULTS: In the 4 weeks to 5 years before index admission, risk factors were present in 209 patients; 182 (87.1%) of the 209 had been in the ED, 104 (49.7%) in an IMW, and 64 (30.6%) in a GMC. The ED showed the greatest potential vaccine coverage, at a cost savings in a best-case scenario; the IMWs showed the best cost-benefit ratio but would provide access to fewer at-risk patients; and a program in the GMC would reach the fewest at-risk patients, with a cost-benefit ratio similar to that of the ED. CONCLUSIONS: The ED in an inner-city hospital has the potential to vaccinate more patients at risk of pneumococcal bacteremia than a GMC or IMWs, and may do so at a cost savings. A prospective evaluation of such a strategy is warranted.
CAS Registry/EC Number
  0 (Pneumococcal Vaccines).
ISSN
  0003-9926
Publication Type
  Journal Article.
Language
  English
Entry Date
  20021008
Revision Date
  20040331
Update Date
  20040401